Qualified Modular Flow Cytometry Immunophenotyping Panels For Use In Clinical Trials Announced
St Charles, MO – October 17, 2016 - Eurofins Bioanalytical Services
Eurofins Bioanalytical Services, a leading provider of large molecule bioanalytical testing announced the launch of two new qualified, modular immunophenotyping flow cytometry panels to support clinical trials. The panels expand the leading GCP-compliant flow cytometry services offered by the Eurofins' sites in the UK and USA.
The first, a TBNK panel, identifies several of the major leukocyte populations, including the CD4 and CD8 subsets, B cells, NK cells, NKT cells lymphocytes and monocytes. The second, a T-helper (Th) panel, identifies several key functional T lymphocyte subsets (Th1, Th2, Th17). The assays are available for use as is, and additionally, due to their modular "drop in - drop out" design, can be readily customized by the removal or addition of markers.
"Eurofins' scientists have developed these two powerful analytical tests for the detection of cell types commonly evaluated in clinical trials," said Dr. Jim Hulse, General Manager of Eurofins Bioanalytical Services. "The modular approach provides the speed and flexibility to add or remove specific markers reliably and easily."
Due to their flexibility, the two assays have numerous applications for immune system monitoring during clinical trials. The cell types identified are often assessed during clinical trials as pharmacodynamic endpoints. The assays are qualified for use with multiple inputs, including whole blood and PBMCs and the robustness of the assays was successfully evaluated by a cross-site validation performed at the testing facilities in Oxford, UK and St. Charles, USA.
For more information, please contact us
Eurofins - a global leader in bio-analysis
Eurofins Bioanalytical Services is a powerhouse large molecule-focused bioanalytical and biomarker contract research organization that, since its formation in 2003, has actively supported the evolving needs of companies developing biotherapeutics.
At our state-of-the-art testing facilities in Oxford, UK and St. Charles, USA we develop, transfer and validate large molecule PK, ADA and biomarker assays to our client's specifications as well as offer a comprehensive listing of pre-qualified assays spanning decades of experience. With industry-leading capacity, we support studies ranging from a single plate to large multinational Phase III clinical trials. We have the capacity to handle variable sample numbers and large volumes to meet the needs of our clients.